The therapeutic efficacy results of a novel immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Biomedicines (September 30, 2022). 

The publication, titled, "Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury"

may be found here ( https://doi.org/10.3390/biomedicines10102449).